United States:
Finding A Way Through A Tight Deal Space
To print this article, all you need is to be registered or login on Mondaq.com.
Last year's contentious U.S. presidential election is often
blamed for the slowdown in dealmaking activity in the life sciences
space. While the uncertainty surrounding that contest certainly had
an impact, Stuart Falber and Belinda Juran see other secular trends
that have made acquisitions and initial public offerings less
attractive — and often impossible — forcing companies
to seek new partnerships and sources of funding.
Click here to continue reading.
Originally published by Above the Law, May 12 2017.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Corporate/Commercial Law from United States
Corporate Transparency Act Update
Shulman Rogers
With the arrival of spring and the first set of Corporate Transparency Act (CTA) filing deadlines behind us, it is a good time for an update on lessons learned from the initial filings.
Compliance Isn't The Only 'AI Washing' Risk
Bracewell
Companies are rapidly adopting artificial intelligence technologies, and both regulators and private plaintiffs have set their sights on "AI washing," where businesses tout AI capabilities that do not exist.